In Madagascar, JSI supported the introduction of HPV vaccine in a two-phase pilot. Lora Shimp and Heather Casciato share the key lessons learned from the program for World Immunization Week.
Today is Innovation Day during World Immunization Week, and there are a lot of innovative ideas out there to reach every child. But innovation doesn’t always require radical new ideas. Sometimes it simply means challenging traditional approaches based on current information. For immunization supply chains, that means changing over 40 years of custom to embrace state-of-the-art commercial best practices.
As we celebrate World Immunization Week April 24-30, 2016, it’s important to remember that one way to “close the gap” on immunization services is by re-examining the wealth of data currently available at the country level and empowering health workers to leverage their historical data to reach their target populations more effectively.
JSI is working to increase immunization rates in Ethiopia through implementation of the Reaching Every District Quality Improvement (RED-QI) approach to promote continuous learning and improvement of the routine immunization system.
HPV affects millions and millions of people. HPV is the most common sexually transmitted infection, and an estimated 20 million people have the active virus at any time, according to WHO. While in the U.S., the HPV vaccine was licensed for girls in 2006, and for boys in 2009, in many other countries, the vaccine is only just being rolled out now. JSI’s Allison Hackbarth and Vanessa Richart describes efforts being made internationally in and in the U.S. to expand access to HPV vaccine.
April 24-30 is World Immunization Week. Mike Favin and Rebecca Fields of the Maternal and Child Survival Program (MCSP) explain how the project is promoting community participation to increase immunization rates using the “My Village, My Home” tool.
Pneumonia is the deadliest disease among children under the age of five, killing an estimated 1.2 million children annually. Fortunately, Pneumococcal Conjugate Vaccine (PCV) can protect susceptible children, preventing against severe forms of pneumococcal diseases—mainly pneumonia, meningitis, bacteremia and sepsis.